GlassScriptPhysician profile
Pamela Mullins
NPI 1740735273
$1,099.32
in general payments reported to CMS, 2019-2025
24 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $254 · 2023: $189 · 2024: $344 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118.96 | 2024-2025 | |
| Baxter Healthcare | $117.60 | 2022 | |
| Lilly USA, LLC | $117.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $114.67 | 2023-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $77.98 | 2021-2025 | Trelegy Ellipta |
| Corium, LLC | $75.31 | 2022-2023 | Azstarys |
| Gilead Sciences, INC. | $58.44 | 2024 | |
| Novo Nordisk INC | $44.19 | 2023-2024 | Ozempic, Tresiba, Rybelsus |
| Cranial Technologies, INC | $42.90 | 2021-2023 | Doc Band |
| Tris Pharma INC | $40.89 | 2022-2023 | Dyanavel Xr |
| Biogen, INC. | $33.77 | 2024-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $31.29 | 2021 | |
| Viiv Healthcare Company | $26.11 | 2024 | Dovato |
| Janssen Pharmaceuticals, INC | $26.09 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $25.28 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.21 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.79 | 2024 | Voquezna |
| Sobi, INC | $18.22 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.19 | 2023 | |
| Seqirus USA INC | $15.89 | 2025 | Flucelvax, Fluad |
| Pfizer INC. | $15.17 | 2025 | |
| Sanofi Pasteur INC. | $14.61 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.45 | 2022 | |
| Organon LLC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.